Advertisement

Pharmacologic Therapy

  • Walter G. ParkEmail author
Chapter
First Online:
  • 1.7k Downloads

Abstract

Current management of severe acute pancreatitis remains primarily supportive with no widely accepted pharmacological abortive therapy in clinical practice. The foundation for developing a promising drug begins with understanding the pathophysiology of acute pancreatitis, which will be briefly reviewed. Specifically, understanding the mechanisms of local and systemic inflammation triggered from acinar injury is important for severe disease. For several decades, various pharmacological agents for pancreatitis have been studied in randomized clinical trials with inconsistent results. These drugs can be categorized by their mechanism of action: anti-secretory agents, protease inhibitors, immunomodulators, antioxidants, and anti-inflammatory agents. Relevant trials will be reviewed and summarized followed by a discussion of future therapeutic opportunities. Such future therapies may come from better understanding and appreciation of the role of the immune system in controlling disease activity. Important strategic steps necessary for developing an effective pharmacological agent for severe acute pancreatitis should focus on reconciling differences between preclinical studies and human clinical trials and standardizing eligibility and outcomes in future clinical trials. Future clinical trials should emphasize more rapid randomization and delivery of medication for earlier interruption of the inflammatory cascade responsible for the significant morbidity and mortality of this disease.

Keywords

Acute Pancreatitis Acinar Cell Systemic Inflammatory Response Syndrome Severe Acute Pancreatitis Mortality Benefit 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology. 2012;143:1179–87 e1–3.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, et al. Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2012;62:102–11.PubMedGoogle Scholar
  3. 3.
    Tenner S, Baillie J, Dewitt J, Vege SS, American College of Gastroenterology. American College of Gastroenterology guideline: management of acute pancreatitis. Am J Gastroenterol. 2013;108:1400–15.PubMedGoogle Scholar
  4. 4.
    Ji B, Logsdon CD. Digesting new information about the role of trypsin in pancreatitis. Gastroenterology. 2011;141:1972–5.PubMedGoogle Scholar
  5. 5.
    Gaisano HY, Gorelick FS. New insights into the mechanisms of pancreatitis. Gastroenterology. 2009;136:2040–4.PubMedGoogle Scholar
  6. 6.
    Mofidi R, Duff MD, Wigmore SJ, Madhavan KK, Garden OJ, Parks RW. Association between early systemic inflammatory response, severity of multiorgan dysfunction and death in acute pancreatitis. Br J Surg. 2006;93:738–44.PubMedGoogle Scholar
  7. 7.
    Frossard JL, Saluja A, Bhagat L, Lee HS, Bhatia M, Hofbauer B, et al. The role of intercellular adhesion molecule 1 and neutrophils in acute pancreatitis and pancreatitis-associated lung injury. Gastroenterology. 1999;116:694–701.PubMedGoogle Scholar
  8. 8.
    Saeki K, Kanai T, Nakano M, Nakamura Y, Miyata N, Sujino T, et al. CCL2-induced migration and SOCS3-mediated activation of macrophages are involved in cerulein-induced pancreatitis in mice. Gastroenterology. 2012;142:1010–20. e9.PubMedGoogle Scholar
  9. 9.
    Demols A, Le Moine O, Desalle F, Quertinmont E, Van Laethem JL, Devière J. CD4(+)T cells play an important role in acute experimental pancreatitis in mice. Gastroenterology. 2000;118:582–90.PubMedGoogle Scholar
  10. 10.
    Zheng L, Xue J, Jaffee EM, Habtezion A. Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. Gastroenterology. 2013;144:1230–40.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Sharif R, Dawra R, Wasiluk K, Phillips P, Dudeja V, Kurt-Jones E, et al. Impact of toll-like receptor 4 on the severity of acute pancreatitis and pancreatitis-associated lung injury in mice. Gut. 2009;58:813–9.PubMedGoogle Scholar
  12. 12.
    Gao HK, Zhou ZG, Li Y, Chen YQ. Toll-like receptor 4 Asp299Gly polymorphism is associated with an increased risk of pancreatic necrotic infection in acute pancreatitis: a study in the Chinese population. Pancreas. 2007;34:295–8.PubMedGoogle Scholar
  13. 13.
    Gloor B, Stahel PF, Muller CA, Schmidt OI, Büchler MW, Uhl W. Predictive value of complement activation fragments C3a and sC5b-9 for development of severe disease in patients with acute pancreatitis. Scand J Gastroenterol. 2003;38:1078–82.PubMedGoogle Scholar
  14. 14.
    Mansfield C. Pathophysiology of acute pancreatitis: potential application from experimental models and human medicine to dogs. J Vet Intern Med. 2012;26:875–87.PubMedGoogle Scholar
  15. 15.
    Hartwig W, Jimenez RE, Fernandez-del Castillo C, Kelliher A, Jones R, Warshaw AL. Expression of the adhesion molecules Mac-1 and L-selectin on neutrophils in acute pancreatitis is protease- and complement-dependent. Ann Surg. 2001;233:371–8.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Liddle RA, Nathan JD. Neurogenic inflammation and pancreatitis. Pancreatology. 2004;4:551–9; discussion 559–60.PubMedGoogle Scholar
  17. 17.
    Griesbacher T. Kallikrein-kinin system in acute pancreatitis: potential of B(2)-bradykinin antagonists and kallikrein inhibitors. Pharmacology. 2000;60:113–20.PubMedGoogle Scholar
  18. 18.
    Steinberg W, Tenner S. Acute pancreatitis. N Engl J Med. 1994;330:1198–210.PubMedGoogle Scholar
  19. 19.
    Easler JJ, Mounzer R, Papachristou GI. Pharmacological therapy for acute pancreatitis: where are we now? Where are we going? Minerva Gastroenterol Dietol. 2012;58:365–76.PubMedGoogle Scholar
  20. 20.
    Durr HK, Maroske D, Zelder O, Bode JC. Glucagon therapy in acute pancreatitis. Report of a double-blind trial. Gut. 1978;19:175–9.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Debas HT, Hancock RJ, Soon-Shiong P, Smythe HA, Cassim MM. Glucagon therapy in acute pancreatitis: prospective randomized double-blind study. Can J Surg. 1980;23:578–80.PubMedGoogle Scholar
  22. 22.
    Kronborg O, Bulow S, Joergensen PM, Svendsen LB. A randomized double-blind trial of glucagon in treatment of first attack of severe acute pancreatitis without associated biliary disease. Am J Gastroenterol. 1980;73:423–5.PubMedGoogle Scholar
  23. 23.
    Cameron JL, Mehigan D, Zuidema GD. Evaluation of atropine in acute pancreatitis. Surg Gynecol Obstet. 1979;148:206–8.PubMedGoogle Scholar
  24. 24.
    Goebell H, Ammann R, Herfarth C, Horn J, Hotz J, Knoblauch M, et al. A double-blind trial of synthetic salmon calcitonin in the treatment of acute pancreatitis. Scand J Gastroenterol. 1979;14:881–9.PubMedGoogle Scholar
  25. 25.
    Greenberg R, Haddad R, Kashtan H, Kaplan O. The effects of somatostatin and octreotide on experimental and human acute pancreatitis. J Lab Clin Med. 2000;135:112–21.PubMedGoogle Scholar
  26. 26.
    Choi TK, Mok F, Zhan WH, Fan ST, Lai EC, Wong J. Somatostatin in the treatment of acute pancreatitis: a prospective randomised controlled trial. Gut. 1989;30:223–7.PubMedPubMedCentralGoogle Scholar
  27. 27.
    D'Amico D, Favia G, Biasiato R, Casaccia M, Falcone F, Fersini M, et al. The use of somatostatin in acute pancreatitis—results of a multicenter trial. Hepatogastroenterology. 1990;37:92–8.PubMedGoogle Scholar
  28. 28.
    Gjorup I, Roikjaer O, Andersen B, Burcharth F, Hovendal C, Pedersen SA, et al. A double-blinded multicenter trial of somatostatin in the treatment of acute pancreatitis. Surg Gynecol Obstet. 1992;175:397–400.PubMedGoogle Scholar
  29. 29.
    Luengo L, Vicente V, Gris F, Coronas JM, Escuder J, Ramón Gomez J, et al. Influence of somatostatin in the evolution of acute pancreatitis. A prospective randomized study. Int J Pancreatol. 1994;15:139–44.PubMedGoogle Scholar
  30. 30.
    Planas M, Perez A, Iglesia R, Porta I, Masclans JR, Bermejo B. Severe acute pancreatitis: treatment with somatostatin. Intensive Care Med. 1998;24:37–9.PubMedGoogle Scholar
  31. 31.
    Andriulli A, Leandro G, Clemente R, Festa V, Caruso N, Annese V, et al. Meta-analysis of somatostatin, octreotide and gabexate mesilate in the therapy of acute pancreatitis. Aliment Pharmacol Ther. 1998;12:237–45.PubMedGoogle Scholar
  32. 32.
    Beechey-Newman N. Controlled trial of high-dose octreotide in treatment of acute pancreatitis. Evidence of improvement in disease severity. Dig Dis Sci. 1993;38:644–7.PubMedGoogle Scholar
  33. 33.
    Binder M, Uhl W, Friess H, Malfertheiner P, Büchler MW. Octreotide in the treatment of acute pancreatitis: results of a unicenter prospective trial with three different octreotide dosages. Digestion. 1994;55 Suppl 1:20–3.PubMedGoogle Scholar
  34. 34.
    McKay C, Baxter J, Imrie C. A randomized, controlled trial of octreotide in the management of patients with acute pancreatitis. Int J Pancreatol. 1997;21:13–9.PubMedGoogle Scholar
  35. 35.
    Karakoyunlar O, Sivrel E, Tanir N, Deneçli AG. High dose octreotide in the management of acute pancreatitis. Hepatogastroenterology. 1999;46:1968–72.PubMedGoogle Scholar
  36. 36.
    Uhl W, Buchler MW, Malfertheiner P, Beger HG, Adler G, Gaus W. A randomised, double blind, multicentre trial of octreotide in moderate to severe acute pancreatitis. Gut. 1999;45:97–104.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Paran H, Mayo A, Paran D, Neufeld D, Shwartz I, Zissin R, et al. Octreotide treatment in patients with severe acute pancreatitis. Dig Dis Sci. 2000;45:2247–51.PubMedGoogle Scholar
  38. 38.
    Yang F, Wu H, Li Y, Li Z, Wang C, Yang J, et al. Prevention of severe acute pancreatitis with octreotide in obese patients: a prospective multi-center randomized controlled trial. Pancreas. 2012;41:1206–12.PubMedGoogle Scholar
  39. 39.
    Arcidiacono R, Gambitta P, Rossi A, Grosso C, Bini M, Zanasi G, et al. The use of a long-acting somatostatin analogue (octreotide) for prophylaxis of acute pancreatitis after endoscopic sphincterotomy. Endoscopy. 1994;26:715–8.PubMedGoogle Scholar
  40. 40.
    Heinrich S, Schafer M, Rousson V, Clavien PA. Evidence-based treatment of acute pancreatitis: a look at established paradigms. Ann Surg. 2006;243:154–68.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Working Group IAPAPAAPG. IAP/APA evidence-based guidelines for the management of acute pancreatitis. Pancreatology. 2013;13:e1–15.Google Scholar
  42. 42.
    Baden H, Jordal K, Lund F, Zachariae F. A double-blind controlled clinical trial of Trasylol. Preliminary results in acute pancreatitis and in prophylaxis against postoperative pancreatitis. Acta Chir Scand Suppl. 1967;378:97–102.PubMedGoogle Scholar
  43. 43.
    Trapnell JE, Rigby CC, Talbot CH, Duncan EH. Proceedings: Aprotinin in the treatment of acute pancreatitis. Gut. 1973;14:828.PubMedGoogle Scholar
  44. 44.
    Trapnell JE, Rigby CC, Talbot CH, Duncan EH. A controlled trial of Trasylol in the treatment of acute pancreatitis. Br J Surg. 1974;61:177–82.PubMedGoogle Scholar
  45. 45.
    Balldin G, Borgstrom A, Genell S, Ohlsson K. The effect of peritoneal lavage and aprotinin in the treatment of severe acute pancreatitis. Res Exp Med (Berl). 1983;183:203–13.Google Scholar
  46. 46.
    Berling R, Genell S, Ohlsson K. High-dose intraperitoneal aprotinin treatment of acute severe pancreatitis: a double-blind randomized multi-center trial. J Gastroenterol. 1994;29:479–85.PubMedGoogle Scholar
  47. 47.
    Berling R, Ohlsson K. Effects of high-dose intraperitoneal aprotinin treatment on complement activation and acute phase response in acute severe pancreatitis. J Gastroenterol. 1996;31:702–9.PubMedGoogle Scholar
  48. 48.
    Smith M, Kocher HM, Hunt BJ. Aprotinin in severe acute pancreatitis. Int J Clin Pract. 2010;64:84–92.PubMedGoogle Scholar
  49. 49.
    Chen CC, Wang SS, Lee FY. Action of antiproteases on the inflammatory response in acute pancreatitis. JOP. 2007;8:488–94.PubMedGoogle Scholar
  50. 50.
    Yang CY, Chang-Chien CS, Liaw YF. Controlled trial of protease inhibitor gabexelate mesilate (FOY) in the treatment of acute pancreatitis. Pancreas. 1987;2:698–700.PubMedGoogle Scholar
  51. 51.
    Harada H, Miyake H, Ochi K, Tanaka J, Kimura I. Clinical trial with a protease inhibitor gabexate mesilate in acute pancreatitis. Int J Pancreatol. 1991;9:75–9.PubMedGoogle Scholar
  52. 52.
    Valderrama R, Perez-Mateo M, Navarro S, Vázquez N, Sanjosé L, Adrián MJ, et al. Multicenter double-blind trial of gabexate mesylate (FOY) in unselected patients with acute pancreatitis. Digestion. 1992;51:65–70.PubMedGoogle Scholar
  53. 53.
    Buchler M, Malfertheiner P, Uhl W, Schölmerich J, Stöckmann F, Adler G, et al. Gabexate mesilate in human acute pancreatitis. German Pancreatitis Study Group. Gastroenterology. 1993;104:1165–70.PubMedGoogle Scholar
  54. 54.
    Pelagotti F, Cecchi M, Messori A. Use of gabexate mesylate in Italian hospitals: a multicentre observational study. J Clin Pharm Ther. 2003;28:191–6.PubMedGoogle Scholar
  55. 55.
    Ino Y, Arita Y, Akashi T, Kimura T, Igarashi H, Oono T, et al. Continuous regional arterial infusion therapy with gabexate mesilate for severe acute pancreatitis. World J Gastroenterol. 2008;14:6382–7.PubMedPubMedCentralGoogle Scholar
  56. 56.
    Takeda K, Matsuno S, Sunamura M, Kakugawa Y. Continuous regional arterial infusion of protease inhibitor and antibiotics in acute necrotizing pancreatitis. Am J Surg. 1996;171:394–8.PubMedGoogle Scholar
  57. 57.
    Takeda K, Yamauchi J, Shibuya K, Sunamura M, Mikami Y, Matsuno S. Benefit of continuous regional arterial infusion of protease inhibitor and antibiotic in the management of acute necrotizing pancreatitis. Pancreatology. 2001;1:668–73.PubMedGoogle Scholar
  58. 58.
    Imaizumi H, Kida M, Nishimaki H, Okuno J, Kataoka Y, Kida Y, et al. Efficacy of continuous regional arterial infusion of a protease inhibitor and antibiotic for severe acute pancreatitis in patients admitted to an intensive care unit. Pancreas. 2004;28:369–73.PubMedGoogle Scholar
  59. 59.
    Piascik M, Rydzewska G, Milewski J, Olszewski S, Furmanek M, Walecki J, et al. The results of severe acute pancreatitis treatment with continuous regional arterial infusion of protease inhibitor and antibiotic: a randomized controlled study. Pancreas. 2010;39:863–7.PubMedGoogle Scholar
  60. 60.
    Konturek SJ, Dembinski A, Konturek PJ, Warzecha Z, Jaworek J, Gustaw P, et al. Role of platelet activating factor in pathogenesis of acute pancreatitis in rats. Gut. 1992;33:1268–74.PubMedPubMedCentralGoogle Scholar
  61. 61.
    Formela LJ, Wood LM, Whittaker M, Kingsnorth AN. Amelioration of experimental acute pancreatitis with a potent platelet-activating factor antagonist. Br J Surg. 1994;81:1783–5.PubMedGoogle Scholar
  62. 62.
    Kingsnorth AN, Galloway SW, Formela LJ. Randomized, double-blind phase II trial of Lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis. Br J Surg. 1995;82:1414–20.PubMedGoogle Scholar
  63. 63.
    McKay CJ, Curran F, Sharples C, Baxter JN, Imrie CW. Prospective placebo-controlled randomized trial of lexipafant in predicted severe acute pancreatitis. Br J Surg. 1997;84:1239–43.PubMedGoogle Scholar
  64. 64.
    Johnson CD, Kingsnorth AN, Imrie CW, McMahon MJ, Neoptolemos JP, McKay C, et al. Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis. Gut. 2001;48:62–9.PubMedPubMedCentralGoogle Scholar
  65. 65.
    Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699–709.PubMedGoogle Scholar
  66. 66.
    Jamdar S, Siriwardena AK. Drotrecogin alfa (recombinant human activated protein C) in severe acute pancreatitis. Crit Care. 2005;9:321–2.PubMedPubMedCentralGoogle Scholar
  67. 67.
    Machala W, Wachowicz N, Komorowska A, Gaszyński W. The use of drotrecogin alfa (activated) in severe sepsis during acute pancreatitis—two case studies. Med Sci Monit. 2004;10:CS31–6.PubMedGoogle Scholar
  68. 68.
    Pettila V, Kyhala L, Kylanpaa ML, Leppäniemi A, Tallgren M, Markkola A, et al. APCAP—activated protein C in acute pancreatitis: a double-blind randomized human pilot trial. Crit Care. 2010;14:R139.PubMedPubMedCentralGoogle Scholar
  69. 69.
    Hackert T, Werner J. Antioxidant therapy in acute pancreatitis: experimental and clinical evidence. Antioxid Redox Signal. 2011;15:2767–77.PubMedGoogle Scholar
  70. 70.
    Siriwardena AK, Mason JM, Balachandra S, Bagul A, Galloway S, Formela L, et al. Randomised, double blind, placebo controlled trial of intravenous antioxidant (n-acetylcysteine, selenium, vitamin C) therapy in severe acute pancreatitis. Gut. 2007;56:1439–44.PubMedPubMedCentralGoogle Scholar
  71. 71.
    Sateesh J, Bhardwaj P, Singh N, Saraya A. Effect of antioxidant therapy on hospital stay and complications in patients with early acute pancreatitis: a randomised controlled trial. Trop Gastroenterol. 2009;30:201–6.PubMedGoogle Scholar
  72. 72.
    Bansal D, Bhalla A, Bhasin DK, Pandhi P, Sharma N, Rana S, et al. Safety and efficacy of vitamin-based antioxidant therapy in patients with severe acute pancreatitis: a randomized controlled trial. Saudi J Gastroenterol. 2011;17:174–9.PubMedPubMedCentralGoogle Scholar
  73. 73.
    Hardy G, Manzanares W. Pharmaconutrition: how has this concept evolved in the last two decades? Nutrition. 2011;27:1090–2.PubMedGoogle Scholar
  74. 74.
    Xue P, Deng LH, Xia Q, Zhang ZD, Hu WM, Yang XN, et al. Impact of alanyl-glutamine dipeptide on severe acute pancreatitis in early stage. World J Gastroenterol. 2008;14:474–8.PubMedPubMedCentralGoogle Scholar
  75. 75.
    Asrani V, Chang WK, Dong Z, Hardy G, Windsor JA, Petrov MS. Glutamine supplementation in acute pancreatitis: a meta-analysis of randomized controlled trials. Pancreatology. 2013;13:468–74.PubMedGoogle Scholar
  76. 76.
    Makela A, Kuusi T, Schroder T. Inhibition of serum phospholipase-A2 in acute pancreatitis by pharmacological agents in vitro. Scand J Clin Lab Invest. 1997;57:401–7.PubMedGoogle Scholar
  77. 77.
    Lankisch PG, Koop H, Winckler K, Kunze H, Vogt W. Indomethacin treatment of acute experimental pancreatitis in the rat. Scand J Gastroenterol. 1978;13:629–33.PubMedGoogle Scholar
  78. 78.
    Ebbehoj N, Friis J, Svendsen LB, Bülow S, Madsen P. Indomethacin treatment of acute pancreatitis. A controlled double-blind trial. Scand J Gastroenterol. 1985;20:798–800.PubMedGoogle Scholar
  79. 79.
    Elmunzer BJ, Scheiman JM, Lehman GA, Chak A, Mosler P, Higgins PD, et al. A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med. 2012;366:1414–22.PubMedPubMedCentralGoogle Scholar
  80. 80.
    Bordas JM, Toledo-Pimentel V, Llach J, Elena M, Mondelo F, Ginès A, et al. Effects of bolus somatostatin in preventing pancreatitis after endoscopic pancreatography: results of a randomized study. Gastrointest Endosc. 1998;47:230–4.PubMedGoogle Scholar
  81. 81.
    Katsinelos P, Fasoulas K, Paroutoglou G, Chatzimavroudis G, Beltsis A, Terzoudis S, et al. Combination of diclofenac plus somatostatin in the prevention of post-ERCP pancreatitis: a randomized, double-blind, placebo-controlled trial. Endoscopy. 2012;44:53–9.PubMedGoogle Scholar
  82. 82.
    Thomopoulos KC, Pagoni NA, Vagenas KA, Margaritis VG, Theocharis GI, Nikolopoulou VN. Twenty-four hour prophylaxis with increased dosage of octreotide reduces the incidence of post-ERCP pancreatitis. Gastrointest Endosc. 2006;64:726–31.PubMedGoogle Scholar
  83. 83.
    Masci E, Cavallini G, Mariani A, Frulloni L, Testoni PA, Curioni S, et al. Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis. Am J Gastroenterol. 2003;98:2182–6.PubMedGoogle Scholar
  84. 84.
    Tsujino T, Komatsu Y, Isayama H, Hirano K, Sasahira N, Yamamoto N, et al. Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled trial. Clin Gastroenterol Hepatol. 2005;3:376–83.PubMedGoogle Scholar
  85. 85.
    Park KT, Kang DH, Choi CW, Cho M, Park SB, Kim HW, et al. Is high-dose nafamostat mesilate effective for the prevention of post-ERCP pancreatitis, especially in high-risk patients? Pancreas. 2011;40:1215–9.PubMedGoogle Scholar
  86. 86.
    Deviere J, Le Moine O, Van Laethem JL, Eisendrath P, Ghilain A, Severs N, et al. Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography. Gastroenterology. 2001;120:498–505.PubMedGoogle Scholar
  87. 87.
    Sherman S, Cheng CL, Costamagna G, Binmoeller KF, Puespoek A, Aithal GP, et al. Efficacy of recombinant human interleukin-10 in prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis in subjects with increased risk. Pancreas. 2009;38:267–74.PubMedGoogle Scholar
  88. 88.
    Sotoudehmanesh R, Khatibian M, Kolahdoozan S, Ainechi S, Malboosbaf R, Nouraie M. Indomethacin may reduce the incidence and severity of acute pancreatitis after ERCP. Am J Gastroenterol. 2007;102:978–83.PubMedGoogle Scholar
  89. 89.
    Khoshbaten M, Khorram H, Madad L, Ehsani Ardakani MJ, Farzin H, Zali MR. Role of diclofenac in reducing post-endoscopic retrograde cholangiopancreatography pancreatitis. J Gastroenterol Hepatol. 2008;23:e11–6.PubMedGoogle Scholar
  90. 90.
    Budzynska A, Marek T, Nowak A, Kaczor R, Nowakowska-Dulawa E. A prospective, randomized, placebo-controlled trial of prednisone and allopurinol in the prevention of ERCP-induced pancreatitis. Endoscopy. 2001;33:766–72.PubMedGoogle Scholar
  91. 91.
    Kwanngern K, Tiyapattanaputi P, Wanitpukdeedecha M, Navicharern P. Can a single dose corticosteroid reduce the incidence of post-ERCP pancreatitis? A randomized, prospective control study. J Med Assoc Thai. 2005;88 Suppl 4:S42–5.PubMedGoogle Scholar
  92. 92.
    Katsinelos P, Kountouras J, Paroutoglou G, Beltsis A, Mimidis K, Zavos C. Intravenous N-acetylcysteine does not prevent post-ERCP pancreatitis. Gastrointest Endosc. 2005;62:105–11.PubMedGoogle Scholar
  93. 93.
    Beauchant M, Ingrand P, Favriel JM, Dupuychaffray JP, Capony P, Moindrot H, et al. Intravenous nitroglycerin for prevention of pancreatitis after therapeutic endoscopic retrograde cholangiography: a randomized, double-blind, placebo-controlled multicenter trial. Endoscopy. 2008;40:631–6.PubMedGoogle Scholar
  94. 94.
    Nojgaard C, Hornum M, Elkjaer M, Hjalmarsson C, Heyries L, Hauge T, et al. Does glyceryl nitrate prevent post-ERCP pancreatitis? A prospective, randomized, double-blind, placebo-controlled multicenter trial. Gastrointest Endosc. 2009;69:e31–7.PubMedGoogle Scholar
  95. 95.
    Nakamichi I, Habtezion A, Zhong B, Contag CH, Butcher EC, Omary MB. Hemin-activated macrophages home to the pancreas and protect from acute pancreatitis via heme oxygenase-1 induction. J Clin Invest. 2005;115:3007–14.PubMedPubMedCentralGoogle Scholar
  96. 96.
    Habtezion A, Kwan R, Yang AL, Morgan ME, Akhtar E, Wanaski SP, et al. Heme oxygenase-1 is induced in peripheral blood mononuclear cells of patients with acute pancreatitis: a potential therapeutic target. Am J Physiol Gastrointest Liver Physiol. 2011;300:G12–20.PubMedPubMedCentralGoogle Scholar
  97. 97.
    Habtezion A, Kwan R, Akhtar E, Wanaski SP, Collins SD, Wong RJ, et al. Panhematin provides a therapeutic benefit in experimental pancreatitis. Gut. 2011;60:671–9.PubMedPubMedCentralGoogle Scholar
  98. 98.
    Davis 3rd AE, Mejia P, Lu F. Biological activities of C1 inhibitor. Mol Immunol. 2008;45:4057–63.PubMedPubMedCentralGoogle Scholar
  99. 99.
    Niederau C, Brinsa R, Niederau M, Lüthen R, Strohmeyer G, Ferrell LD. Effects of C1-esterase inhibitor in three models of acute pancreatitis. Int J Pancreatol. 1995;17:189–96.PubMedGoogle Scholar
  100. 100.
    Yamaguchi H, Weidenbach H, Luhrs H, Lerch MM, Dickneite G, Adler G. Combined treatment with C1 esterase inhibitor and antithrombin III improves survival in severe acute experimental pancreatitis. Gut. 1997;40:531–5.PubMedPubMedCentralGoogle Scholar
  101. 101.
    Testoni PA, Cicardi M, Bergamaschini L, Guzzoni S, Cugno M, Buizza M, et al. Infusion of C1-inhibitor plasma concentrate prevents hyperamylasemia induced by endoscopic sphincterotomy. Gastrointest Endosc. 1995;42:301–5.PubMedGoogle Scholar
  102. 102.
    Schneider DT, Nurnberger W, Stannigel H, Bönig H, Göbel U. Adjuvant treatment of severe acute pancreatitis with C1 esterase inhibitor concentrate after haematopoietic stem cell transplantation. Gut. 1999;45:733–6.PubMedPubMedCentralGoogle Scholar
  103. 103.
    Bernstein JA. On-demand therapy for hereditary angioedema. Immunol Allergy Clin North Am. 2013;33:487–94.PubMedGoogle Scholar
  104. 104.
    Keating GM. Eculizumab: a review of its use in atypical haemolytic uraemic syndrome. Drugs. 2013;73(18):2053–66.PubMedGoogle Scholar
  105. 105.
    Fluhr G, Mayerle J, Weber E, Aghdassi A, Simon P, Gress T, et al. Pre-study protocol MagPEP: a multicentre randomized controlled trial of magnesium sulphate in the prevention of post-ERCP pancreatitis. BMC Gastroenterol. 2013;13:11.PubMedPubMedCentralGoogle Scholar
  106. 106.
    Chen HM, Chen JC, Hwang TL, Jan YY, Chen MF. Prospective and randomized study of gabexate mesilate for the treatment of severe acute pancreatitis with organ dysfunction. Hepatogastroenterology. 2000;47:1147–50.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Departments of Medicine and GastroenterologyStanford University Medical CenterStanfordUSA
  2. 2.Pancreas Clinic, Stanford UniversityStanfordUSA

Personalised recommendations

Cite chapter

Buy options